PlumX Metrics
Embed PlumX Metrics

Cationic liposomal vaccine adjuvants in animal challenge models: Overview and current clinical status

Expert Review of Vaccines, ISSN: 1476-0584, Vol: 11, Issue: 5, Page: 561-577
2012
  • 38
    Citations
  • 0
    Usage
  • 41
    Captures
  • 0
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

  • Citations
    38
    • Citation Indexes
      35
    • Patent Family Citations
      2
      • Patent Families
        2
    • Policy Citations
      1
      • Policy Citation
        1
  • Captures
    41

Review Description

Cationic liposome formulations can function as efficient vaccine adjuvants. However, due to the highly diverse nature of lipids, cationic liposomes have different physical-chemical characteristics that influence their adjuvant mechanisms and their relevance for use in different vaccines. These characteristics can be further manipulated by incorporation of additional lipids or stabilizers, and inclusion of carefully selected immunostimulators is a feasible strategy when tailoring cationic liposomal adjuvants for specific disease targets. Thus, cationic liposomes present a plasticity, which makes them promising adjuvants for future vaccines. This versatility has also led to a vast amount of literature on different experimental liposomal formulations in combination with a wide range of immunostimulators. Here, we have compiled information about the animal challenge models and administration routes that have been used to study vaccine adjuvants based on cationic liposomes and provide an overview of the applicability, progress and clinical status of cationic liposomal vaccine adjuvants. © 2012 Expert Reviews Ltd.

Bibliographic Details

Korsholm, Karen Smith; Andersen, Peter Lawætz; Christensen, Dennis

Informa UK Limited

Immunology and Microbiology; Biochemistry, Genetics and Molecular Biology; Pharmacology, Toxicology and Pharmaceutics

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know